- Conditions
- Skin Irritation
- Interventions
- 4 placebo, 4 Vitamin D, Valchlor
- Dietary Supplement · Drug
- Lead sponsor
- University Hospitals Cleveland Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1105–1128
of 1,419
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Gastroesophageal Reflux Disease (GERD)
- Interventions
- Open Label Run In Esomeprazole, Double Blind Esomeprazole, Double Blind Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 1 Month to 11 Months
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Atlanta, Georgia • Park Ridge, Illinois + 11 more
- Conditions
- Noninfectious Uveitis
- Interventions
- LX211
- Drug
- Lead sponsor
- Lux Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 28
- States / cities
- Peoria, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 24 more
- Conditions
- Tardive Dyskinesia (TD)
- Interventions
- Valbenazine, Placebo oral capsule
- Drug
- Lead sponsor
- Neurocrine Biosciences
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 42
- States / cities
- Little Rock, Arkansas • Anaheim, California • Costa Mesa, California + 35 more
- Conditions
- Healthy
- Interventions
- Palbociclib Formulation Reference, Palbociclib Formulation Test
- Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Recurrent Gastrointestinal Symptoms
- Interventions
- Trenev Trio®/Healthy Trinity®, Placebo
- Dietary Supplement
- Lead sponsor
- Sprim Advanced Life Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 5
- States / cities
- Los Angeles, California • San Francisco, California • West Lawn, Pennsylvania + 2 more
- Conditions
- Diabetes
- Interventions
- MBX-2982, Sitagliptin, placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Las Vegas, Nevada • Binghamton, New York + 1 more
- Conditions
- Essential Hypertension
- Interventions
- LCI699, Eplerenone, LCI699-matching Placebo, Eplerenone-matching Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 628 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- FDC tiotropium / salmeterol, Placebo, Salmeterol, Tiotropium (Spiriva®)
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 20
- States / cities
- Boulder, Colorado • Wheat Ridge, Colorado • Winter Park, Florida + 16 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- Tegobuvir (GS-9190), GS-9451, Pegasys®, Copegus®, Tegobuvir placebo, GS-9451 placebo
- Drug · Biological
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 245 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 85
- States / cities
- Dothan, Alabama • Montgomery, Alabama • Phoenix, Arizona + 62 more
- Conditions
- Major Depressive Disorder
- Interventions
- SPD489 (Lisdexamfetamine dimesylate), Matching placebo
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 143 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 33
- States / cities
- Imperial, California • Los Alamitos, California • Oceanside, California + 28 more
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- PT005 MDI, Formoterol Fumarate 12 μg (Foradil® Aerolizer®), Formoterol Fumarate 24 μg (Foradil® Aerolizer®), Placebo MDI
- Drug · Other
- Lead sponsor
- Pearl Therapeutics, Inc.
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 3
- States / cities
- Clearwater, Florida • Tampa, Florida • Spartanburg, South Carolina
- Conditions
- Cystic Fibrosis (CF)
- Interventions
- ABBV-576, Galicaftor, Placebo, Navocaftor, ABBV-119
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 22
- States / cities
- Mobile, Alabama • Los Angeles, California • Ventura, California + 19 more
- Conditions
- Exercise Physiology, Nutritional Supplementation
- Interventions
- Caffeine, L-Citrulline, Exogenous Ketone (Beta-Hydroxybutyrate), placebo beverage
- Dietary Supplement · Other
- Lead sponsor
- St. Louis University
- Other
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Systemic Lupus Erythematosus (Sle)
- Interventions
- Nicotinamide Riboside
- Dietary Supplement
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years to 120 Years · Female only
- Enrollment
- 78 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Relapsed/Refractory Peripheral T-cell Lymphoma
- Interventions
- Tolinapant, Decitabine + Cedazuridine
- Drug
- Lead sponsor
- Taiho Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 6
- States / cities
- Aurora, Colorado • Tampa, Florida • Atlanta, Georgia + 3 more
- Conditions
- Healthy Volunteers
- Interventions
- ID-Capsule- Active, Wearable Sensor, Placebo
- Device
- Lead sponsor
- EtectRX, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Sickle Cell Disease, Sickle-Cell; Hb-SC, Sickle Beta 0 Thalassemia
- Interventions
- IMR-687, Placebo Oral Capsule
- Drug
- Lead sponsor
- Cardurion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Dysmenorrhea, Chronic Pelvic Pain, Pelvic Pain
- Interventions
- Naproxen Sodium 550mg, Placebo, Extended Release Acetaminophen (650 mg)
- Drug
- Lead sponsor
- Endeavor Health
- Other
- Eligibility
- 18 Years to 35 Years · Female only
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Evanston, Illinois
- Conditions
- Advanced Solid Tumors, Metastatic Colon Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Rectal Cancer
- Interventions
- Fruquintinib (HMPL-013)
- Drug
- Lead sponsor
- Hutchison Medipharma Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • San Marcos, California • Santa Rosa, California + 6 more
- Conditions
- Colorectal Cancer
- Interventions
- Fruquintinib
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 44
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Tucson, Arizona + 34 more
- Conditions
- Onychomycosis
- Interventions
- Itraconazole 100mg capsules, Itraconazole 200mg tablets, Placebo tablets
- Drug
- Lead sponsor
- Stiefel, a GSK Company
- Industry
- Eligibility
- 16 Years to 75 Years
- Enrollment
- 1,381 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 52
- States / cities
- Birmingham, Alabama • Tuscon, Arizona • Hot Springs, Arkansas + 43 more
- Conditions
- MDS
- Interventions
- Decitabine
- Drug
- Lead sponsor
- Treebough Therapies
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Hepatitis C, HCV, Chronic Hepatitis C Infection, Hepatitis C Genotype 1
- Interventions
- ABT-450, ABT-072, ABT-333, Ritonavir, Peginterferon alpha-2a, Ribavirin, Placebo
- Drug · Other
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Anaheim, California • La Jolla, California + 19 more